Positive Opinion, Program Honorees, Positive Medical Results, and Investor Day - Research Report on Bristol-Myers Squibb, Ariad

Positive Opinion, Program Honorees, Positive Medical Results, and Investor Day
   - Research Report on Bristol-Myers Squibb, Ariad Pharmaceuticals, Dyax,
                  Ironwood Pharmaceuticals, and Immunomedics

Editor Note: For more information about this release, please scroll to bottom.

PR Newswire

NEW YORK, November 27, 2013

NEW YORK, November 27, 2013 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting
Bristol-Myers Squibb Company (NYSE: BMY), Ariad Pharmaceuticals Inc. (NASDAQ:
ARIA), Dyax Corp. (NASDAQ: DYAX), Ironwood Pharmaceuticals Inc. (NASDAQ:
IRWD), and Immunomedics Inc. (NASDAQ: IMMU). Today's readers may access these
reports free of charge - including full price targets, industry analysis and
analyst ratings - via the links below.

Bristol-Myers Squibb Company Research Report

On November 22, 2013, Bristol-Myers Squibb Company (Bristol-Myers Squibb),
together with AstraZeneca, announced that the Committee for Medicinal Products
for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a
positive opinion, recommending the approval of Xigduo™ (dapagliflozin and
metformin hydrochloride) for 18 years and older adults with type 2 diabetes
mellitus as an adjunct to diet and exercise for improving glycaemic control in
patients inadequately controlled on their current metformin-based treatment
regimen or who are currently being treated with the combination of
dapagliflozin and metformin as separate tablets. Bristol-Myers Squibb informed
that CHMP's positive opinion will now be reviewed by the European Commission,
which holds the authority to approve medicines for the EU. The Company added
that the final decision will be applicable to all 28 EU member countries plus
Iceland and Norway. The Full Research Report on Bristol-Myers Squibb Company -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/81a9_BMY

Ariad Pharmaceuticals Inc. Research Report

On November 22, 2013, Ariad Pharmaceuticals Inc. (Ariad Pharmaceuticals)
announced the adoption of a positive opinion by the Committee for Human
Medicinal Products (CHMP) of the European Medicines Agency (EMA) on the
continued availability of the Company's Iclusig (ponatinib) in the EU for use
in patients in its authorized indications. The Company added that subsequent
to its review of updated clinical-trial data on Iclusig, the CHMP made
recommendations on measures to help reduce the risk of occlusive vascular
events in patients taking Iclusig. Jonathan E. Dickinson, General Manager,
ARIAD Pharmaceuticals commented, "The conclusions reached by the CHMP, which
were announced today, confirm a positive benefit-risk assessment for Iclusig
after considering the most recent safety information." The Full Research
Report on Ariad Pharmaceuticals Inc. - including full detailed breakdown,
analyst ratings and price targets - is available to download free of charge
at:

http://www.analystscorner.com/r/full_research_report/161c_ARIA

Dyax Corp. Research Report

On November 21, 2013, Dyax Corp. (Dyax) announced five HAE Allies honorees
selected for recognition by the HAE Allies program for their contributions in
supporting individuals with hereditary angioedema (HAE) to live life to the
fullest. Dyax stated that the HAE Allies program hopes to highlight the value
of support for those living with hereditary angioedema, a potentially
life-threatening condition characterized by spontaneous episodes of swelling
in the face, feet, hands, throat and abdomen, by drawing from the inspiring
stories of individuals nationwide. The Company informed that honorees were
selected by a multi-disciplinary council of HAE experts organized by Dyax,
which develops and markets KALBITOR (ecallantide) for the treatment of sudden
attacks of HAE in patients 16 years of age and older. Gustav Christensen,
President and CEO of Dyax stated, "A support network is essential to those
living with HAE. These honorees truly exemplify the meaningful difference
individuals can make for someone struggling with a rare disease." The Full
Research Report on Dyax Corp. - including full detailed breakdown, analyst
ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/58ae_DYAX

Ironwood Pharmaceuticals Inc. Research Report

On November 21, 2013, Ironwood Pharmaceuticals Inc. (Ironwood) announced that
it will hold its Investor Day on December 12, 2013, starting at 8:30 a.m. ET
in New York City. The Company stated that its leadership team members will
provide an in-depth review of the Company, including progress and insights
regarding its research, development and commercial efforts. Ironwood added
that the live webcast of the event can be accessed via Investors section of
the Company's website, and replay of the same will also be available for 90
days at the same location. The Full Research Report on Ironwood
Pharmaceuticals Inc. - including full detailed breakdown, analyst ratings and
price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/dbc4_IRWD

Immunomedics Inc. Research Report

On November 8, 2013, Immunomedics Inc. (Immunomedics) announced that some
patients who had failed prior therapy with irinotecan or camptosar, both
topoisomerase-1 inhibitors, responded to IMMU-132, the Company's lead
antibody-drug conjugate (ADC) in clinical development for the treatment of
patients with solid cancers. According to the release, Dr. Allyson Ocean of
Weill-Cornell Medical College, New York, was invited by the Program Chairs to
present the updated results at the Symposium, which is jointly organized by
the Mount Sinai School of Medicine and the Chemotherapy Foundation, in
collaboration with The Tisch Cancer Institute. The Company stated that out of
the 18 patients who responded to IMMU-132, 8 had failed prior therapies with
irinotecan or camptosar. Immunomedics added that since irinotecan is the
parent of SN-38, the Company's drug of choice in IMMU-132, it postulates that
the increased amount of SN-38 delivered to the tumors by IMMU-132 overcomes
the tumor's resistance to this class of drugs. Immunomedics informed that the
study was supported in part by Award Number R43CA171388 from the National
Cancer Institute. The Full Research Report on Immunomedics Inc. - including
full detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:

http://www.analystscorner.com/r/full_research_report/c20d_IMMU

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Namrata Maheshwari, a CFA charterholder. However, we
    are only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Namrata Maheshwari,
CFA, has only reviewed the information provided by Equity News Network in this
article or report according to the Procedures outlined by Equity News Network.
Equity News Network is not entitled to veto or interfere in the application of
such procedures by the outsourced provider to the articles, documents or
reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

www.AnalystsCorner.com

SOURCE Analysts' Corner

Contact: Joe Thomas; +1-310-496-8071 (North America)
 
Press spacebar to pause and continue. Press esc to stop.